**Ketamine:** Elon Musk defends controversial use in heated Don Lemon interview

San Francisco, CA – Tesla CEO Elon Musk discussed the benefits of his ketamine prescription for Tesla investors during a video interview with former CNN anchor Don Lemon. In the interview conducted earlier this month, Musk mentioned that the drug helps him manage a negative chemical state similar to depression. Despite canceling the partnership shortly after the interview, Musk emphasized the importance of execution for Wall Street investors. He leads not only Tesla but also the rocket company SpaceX and the social media platform X, arguing that Tesla’s value is on par with the entire car industry combined.

A Wall Street Journal investigation published in January raised concerns about Musk’s alleged use of illegal drugs such as LSD, cocaine, ecstasy, and psychedelic mushrooms, causing worry among executives and board members at his companies. The report highlighted potential violations of federal policies that could jeopardize SpaceX’s government contracts. Additionally, it was reported that one Tesla director decided not to stand for re-election to the board in 2019 due to frustrations with Musk’s behavior.

Responding to the Journal report, Musk stated that he agreed to three years of random drug testing at the request of NASA, SpaceX’s partner, to ensure compliance. He reassured that no trace amounts of any drugs or alcohol were found. In the Lemon interview, Musk disclosed that he has a doctor’s prescription for ketamine and estimated that he takes a small amount every other week.

In the video interview, Lemon questioned Musk about the potential implications of his ketamine use on government contracts, clearances, and Wall Street. Musk’s explanation of his ketamine use shed light on his perspective. Lemon later shared the interview on YouTube and X platforms after Musk abruptly ended “The Don Lemon Show” partnership on X, where Lemon was set to host three 30-minute episodes per week. Musk expressed dissatisfaction with Lemon’s approach, dismissing it as resembling CNN but on social media, a strategy that Musk deemed ineffective.

Despite requests for comment, Musk did not respond to Reuters. This interaction between Musk and Lemon provides a glimpse into the complexities surrounding Musk’s drug use, business endeavors, and media partnerships. Lemon’s efforts to engage with Musk on these topics offer insight into the challenges and controversies faced by prominent figures like Musk in managing personal and professional responsibilities.